Naga Pannala
Cardiovascular Disease · Midfield, ALNPI 1366673352
Payments from drug & device makers
Across 95 payments — averaging $36.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$690
- Medtronic$671
- Johnson & Johnson$353
- Medical Device Business Services, Inc.$327
- Amgen$321
- E.r. Squibb & Sons, L.L.C.$304
- plus $794 from 15 others
What the payments were for
- Travel & lodging$92027%
- Food & beverage$2,53973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 5 | $690 |
| Medtronic(2 entities) | 11 | $671 |
| Johnson & Johnson | 17 | $353 |
| Medical Device Business Services, Inc. | 1 | $327 |
| Amgen | 14 | $321 |
| E.r. Squibb & Sons, L.L.C. | 7 | $304 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $116 |
| Amarin Pharma, Inc. | 6 | $105 |
| Novartis | 5 | $95 |
| Journey Medical Corporation | 1 | $86 |
| Sanofi-aventis U.S. LLC | 3 | $67 |
| Regeneron Healthcare Solutions, Inc. | 3 | $65 |
| Bardy Diagnostics, Inc. | 3 | $48 |
| Boehringer Ingelheim | 2 | $46 |
| Pfizer | 2 | $35 |
| AstraZeneca | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Novo Nordisk | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$585
- Carto 3$327
- ELIQUIS$217
- Reveal LINQ$150
How this compares
$3,459 in reported general payments places this provider in the 50th percentile of 292 cardiovascular disease providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 12 | $9,864 |
| Nitroglycerin | 16 | $145 |
| Metoprolol Succinate | 19 | $102 |
| Amlodipine Besylate | 18 | $96 |
| Spironolactone | 13 | $93 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 16 | $79 |
| Furosemide | 11 | $53 |
| Atorvastatin Calcium | 11 | $51 |
| Hydrochlorothiazide | 16 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $95 | $9,86412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Midfield
- Mustafa AhmedBirmingham$2.5M
- Brian FoleyAlexander City$2.5M
- Andreas MuenchDothan$2M
- Alain BouchardBirmingham$1.9M
- William DavisAuburn$1.7M
- Walter HaughtHuntsville$1.6M
- Christopher BrownMobile$1.4M
- Shi-Chi ChengHuntsville$1.2M
- Mahomed SalameAnniston$1.2M
- Steven JonesBirmingham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.